Immuneering Corp (IMRX) stock
IMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.71+0.04 (+1.09%)
Close on Nov 13, 2026Market cap $240.27MP/E –Yield –
Immuneering cash
Cash and short-term investments held at the end of each period.
Immuneering's cash was $58.23M at Sep 30, 2026. For fiscal 2025 it was $128.65M, up 255.9% from the year before. The highest annual figure on record is $149.20M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $128.65M | +255.9% |
| FY2024 | Dec 31, 2024 | $36.14M | -57.8% |
| FY2023 | Dec 31, 2023 | $85.67M | -18.8% |
| FY2022 | Dec 31, 2022 | $105.52M | -29.3% |
| FY2021 | Dec 31, 2021 | $149.20M | +302.3% |
| FY2020 | Dec 31, 2020 | $37.09M | +169.1% |
| FY2019 | Dec 31, 2019 | $13.78M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $58.23M | -74.4% |
| Q2 FY2026 | Jun 30, 2026 | $41.32M | +56.8% |
| Q1 FY2026 | Mar 31, 2026 | $47.32M | +31.9% |
| Q4 FY2025 | Dec 31, 2025 | $128.65M | +255.9% |
| Q3 FY2025 | Sep 30, 2025 | $227.56M | +349.2% |
| Q2 FY2025 | Jun 30, 2025 | $26.36M | -55.9% |
| Q1 FY2025 | Mar 31, 2025 | $35.87M | -49.7% |
| Q4 FY2024 | Dec 31, 2024 | $36.14M | -57.8% |
| Q3 FY2024 | Sep 30, 2024 | $50.66M | -47.9% |
| Q2 FY2024 | Jun 30, 2024 | $59.73M | -45.2% |
| Q1 FY2024 | Mar 31, 2024 | $71.29M | -22.1% |
| Q4 FY2023 | Dec 31, 2023 | $85.67M | -18.8% |
| Q3 FY2023 | Sep 30, 2023 | $97.24M | -17.0% |
| Q2 FY2023 | Jun 30, 2023 | $108.99M | -14.9% |
| Q1 FY2023 | Mar 31, 2023 | $91.54M | -33.6% |
| Q4 FY2022 | Dec 31, 2022 | $105.52M | -29.3% |
| Q3 FY2022 | Sep 30, 2022 | $117.20M | -21.6% |
| Q2 FY2022 | Jun 30, 2022 | $128.10M | +155.0% |
| Q1 FY2022 | Mar 31, 2022 | $137.77M | +345.4% |
| Q4 FY2021 | Dec 31, 2021 | $149.20M | +302.3% |
| Q3 FY2021 | Sep 30, 2021 | $149.48M | +2570.5% |
| Q2 FY2021 | Jun 30, 2021 | $50.25M | +452.8% |
| Q1 FY2021 | Mar 31, 2021 | $30.93M | +124.4% |
| Q4 FY2020 | Dec 31, 2020 | $37.09M | – |
| Q3 FY2020 | Sep 30, 2020 | $5.60M | – |
| Q2 FY2020 | Jun 30, 2020 | $9.09M | – |
| Q4 FY2019 | Dec 31, 2019 | $13.78M | – |
See a number that looks wrong?